Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...
CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino ...
Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin. With the 2025 European Society of Medical Oncology (ESMO) Congress starting on ...
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, ...
When the organization now called the European Society for Medical Oncology (ESMO) opens its 50th anniversary Congress ...
A MAFS star has broken their silence after being cruelly targeted by a vile death hoax after their brave cancer battle. The ...
A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...
Researchers in China combined findings from MRI scans with clinical features to create a new predictive model for nonmuscle-invasive bladder cancer recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback